[go: up one dir, main page]

DK1961420T3 - Middel til forebyggelse og behandling af akut nyresvigt - Google Patents

Middel til forebyggelse og behandling af akut nyresvigt

Info

Publication number
DK1961420T3
DK1961420T3 DK06834797.0T DK06834797T DK1961420T3 DK 1961420 T3 DK1961420 T3 DK 1961420T3 DK 06834797 T DK06834797 T DK 06834797T DK 1961420 T3 DK1961420 T3 DK 1961420T3
Authority
DK
Denmark
Prior art keywords
prevention
treatment
kidney failure
acute kidney
acute
Prior art date
Application number
DK06834797.0T
Other languages
English (en)
Inventor
Soroku Yagihashi
Saori Ogasawara
Chihiro Hibi
Noriaki Kato
Original Assignee
Sanwa Kagaku Kenkyusho Co
Univ Hirosaki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanwa Kagaku Kenkyusho Co, Univ Hirosaki filed Critical Sanwa Kagaku Kenkyusho Co
Application granted granted Critical
Publication of DK1961420T3 publication Critical patent/DK1961420T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK06834797.0T 2005-12-16 2006-12-15 Middel til forebyggelse og behandling af akut nyresvigt DK1961420T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005362579 2005-12-16
PCT/JP2006/325054 WO2007069727A1 (ja) 2005-12-16 2006-12-15 急性腎不全の予防または治療剤

Publications (1)

Publication Number Publication Date
DK1961420T3 true DK1961420T3 (da) 2012-08-27

Family

ID=38163029

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06834797.0T DK1961420T3 (da) 2005-12-16 2006-12-15 Middel til forebyggelse og behandling af akut nyresvigt

Country Status (11)

Country Link
US (1) US20080319038A1 (da)
EP (1) EP1961420B1 (da)
JP (1) JP5107053B2 (da)
KR (1) KR101350226B1 (da)
CN (1) CN101325952B (da)
AU (1) AU2006325947B2 (da)
CA (1) CA2633481C (da)
DK (1) DK1961420T3 (da)
ES (1) ES2393271T3 (da)
PL (1) PL1961420T3 (da)
WO (1) WO2007069727A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5550152B2 (ja) 2008-10-02 2014-07-16 エルジー・ケム・リミテッド 光学フィルム及びその製造方法
JP5212849B2 (ja) 2010-01-14 2013-06-19 株式会社三和化学研究所 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬
CA2791360A1 (en) 2010-04-28 2011-11-03 Sanwa Kagaku Kenkyusho Co., Ltd. A pharmaceutical for preventing or treating an inner ear disorder
JP2015110525A (ja) * 2012-04-02 2015-06-18 株式会社三和化学研究所 歯肉炎の予防又は治療のための医薬
US11426386B2 (en) 2014-12-05 2022-08-30 Case Western Reserve University Compositions and methods of modulating S-nitrosylation
EP3226859B1 (en) * 2014-12-05 2025-03-26 Case Western Reserve University Akr1a1 inhibitors for use in lowering cholesterol and modulate s-nitrosylation
CA3076889A1 (en) 2017-09-25 2019-03-28 Case Western Reserve University Compositions and methods of reducing serum cholesterol and pcsk9
WO2020005938A1 (en) 2018-06-25 2020-01-02 Case Western Reserve University Compositions and methods for treating tissue injury
EP3852750A4 (en) 2018-09-21 2022-05-11 Case Western Reserve University Aldoketo reductase inhibitors and uses thereof
US12391703B2 (en) 2019-09-23 2025-08-19 Case Western Reserve University Aldoketo reductase inhibitors and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61200991A (ja) * 1985-03-04 1986-09-05 Sanwa Kagaku Kenkyusho:Kk スピロ―３―ヘテロアゾリジン化合物、その製法及びそれを有効成分とする糖尿病合併症の予防及び治療剤
DE3769066D1 (de) * 1986-08-28 1991-05-08 Sanwa Kagaku Kenkyusho Co Hydantoin-derivate zur behandlung von komplikationen bei diabetes.
US5164391A (en) * 1989-09-20 1992-11-17 Sanwa Kagaku Kenkyusho Co., Ltd. Hydantoin derivatives for treating complications of diabetes and circulatory diseases
JP2997892B2 (ja) * 1990-10-05 2000-01-11 株式会社三和化学研究所 ヒダントイン誘導体を有効成分とする循環器系疾患の予防及び治療剤
JP2997894B2 (ja) 1990-11-07 2000-01-11 株式会社三和化学研究所 循環器系疾患の予防及び治療剤
JP3267698B2 (ja) 1992-10-27 2002-03-18 株式会社三和化学研究所 ヒダントイン誘導体及びその塩並びにこれらを有効成分とするメイラード反応阻害剤
JPH07242547A (ja) 1994-03-02 1995-09-19 Sanwa Kagaku Kenkyusho Co Ltd 糖尿病性単純網膜症の進行阻止剤乃至治療剤
JP3603129B2 (ja) 1994-12-28 2004-12-22 株式会社三和化学研究所 糖尿病性角膜症の治療剤
IL120264A0 (en) * 1996-02-29 1997-06-10 Pfizer Method of reducing tissue damage associated with non-cardiac ischemia
US6426341B1 (en) * 1999-06-30 2002-07-30 Pfizer Inc. Treatment for diabetic complications
AU761191B2 (en) * 2001-05-24 2003-05-29 Pfizer Products Inc. Therapies for tissue damage resulting from ischemia
US6998404B2 (en) 2001-08-08 2006-02-14 Genomed, Llc Treatment or prevention of acute renal failure
TWI353979B (en) * 2002-04-10 2011-12-11 Nippon Zoki Pharmaceutical Co Novel crystal form of 5-hydroxy-1-methylhydantoin
WO2003105864A1 (en) * 2002-06-13 2003-12-24 Board Of Regents, The University Of Texas System Methods and compositions involving aldose reductase inhibitors
JP2004300153A (ja) * 2003-03-20 2004-10-28 Kiyoshi Kurokawa 蛋白修飾物生成抑制剤
US20070060533A1 (en) * 2003-10-24 2007-03-15 Meiji Seika Kaisha Ltd. Novel inhibitor of the formation of advanced glycation end product and aldose reductase inhibitor
WO2005072066A2 (ja) * 2004-01-30 2005-08-11 Sanwa Kagaku Kenkyusho Co 糖尿病黄斑症の予防又は治療剤
CN1921853A (zh) * 2004-02-20 2007-02-28 株式会社三和化学研究所 重度糖尿病性视网膜病的预防或治疗剂

Also Published As

Publication number Publication date
EP1961420A4 (en) 2010-12-15
US20080319038A1 (en) 2008-12-25
CA2633481A1 (en) 2007-06-21
EP1961420A1 (en) 2008-08-27
HK1126123A1 (en) 2009-08-28
PL1961420T3 (pl) 2012-12-31
KR20080097400A (ko) 2008-11-05
EP1961420B1 (en) 2012-07-25
CN101325952B (zh) 2012-02-08
CA2633481C (en) 2013-12-17
JPWO2007069727A1 (ja) 2009-05-28
ES2393271T3 (es) 2012-12-19
AU2006325947A1 (en) 2007-06-21
WO2007069727A1 (ja) 2007-06-21
CN101325952A (zh) 2008-12-17
AU2006325947B2 (en) 2011-09-01
JP5107053B2 (ja) 2012-12-26
KR101350226B1 (ko) 2014-01-13

Similar Documents

Publication Publication Date Title
DK1824475T3 (da) Fremgangsmåde til oprensning af trans-(-)-delta9-tetrahydrocannabinol og trans-(+)-delta9-tetrahydrocannabinol
DK2084151T3 (da) Substituerede dihydropyrazoloner til behandling af kardiovaskulære og hæmatologiske sygdomme
DK1877232T3 (da) Fremgangsmåde til behandling af træoverflader
DK3121169T3 (da) Fremgangsmåder til syntese og/eller oprensning af diaminophenothiaziniumforbindelser
DK1805312T3 (da) Fremgangsmåder og midler til fremstilling af hyaluronan
DK2030476T3 (da) Fremgangsmåde og system til forbedring af forståeligheden af lyde
CY2200156T2 (el) Επεξεργασια λυματων
DK2518655T3 (da) Anordning og fremgangsmåde til forebyggelse af hypoglykæmi
DK2120604T3 (da) Fremgangsmåde til fraktionering af havre, produkter derved opnået, og anvendelser deraf
DK2687223T4 (da) Påvisning og behandling af demens
DK1942898T4 (da) Dipeptidylpeptidase-inhibitorer til behandling af diabetes
DK1928850T3 (da) Midler til forebyggelse og behandling af lidelser, der involverer modulering af RyR-receptorerne
DK2079485T3 (da) Phenylpropionamidforbindelser og anvendelsen deraf
DK1685834T3 (da) Anvendelse af pinolensyre til behandling af obesitet
DK3403657T3 (da) Anvendelse af oligouronater til behandling af slimhyperviskositet
DK2131940T3 (da) Indretning til behandling af vand, især filterindretning, og kartusche
NO20054709L (no) Sammenfoyningssystem og anvendelse av dette
DK1948176T3 (da) Diarylurinstoffer til behandling af pulmonær hypertension
DK3067068T3 (da) Natrium-meta-arsenit til anvendelse i behandlingen af myelomatose
DE602006019395D1 (de) Media-behandlungseinrichtung
DK2234631T3 (da) Forbindelser og fremgangsmåder til behandling af vaskulær sygdom
DK1734959T3 (da) Forbindelser til behandling af skizofreni og/eller glukoregulerende abnormaliteter
DK1905452T3 (da) Middel til forebyggelse eller behandling af glaukom
DK1961420T3 (da) Middel til forebyggelse og behandling af akut nyresvigt
DK1968574T3 (da) Anvendelse af benzokondenserede heterocykliske sulfamidderivater til behandling af obesitet